Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic Leukemia
John H. Kersey(University of Minnesota), Norma K.C. Ramsay(University of Minnesota), Daniel Weisdorf(University of Minnesota), Daniel A. Vallera(University of Minnesota), Tucker W. LeBien(University of Minnesota), Tae Il Kim(Yonsei University), Mark E. Nesbit(The Wistar Institute), Philip B. McGlave(University of Minnesota), Anne I. Goldman(Meir Medical Center), Bruce Bostrom(Minnesota West Community & Technical College), David D. Hurd(Duke University), William G. Woods(Emory University)
Cited by 334
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Virus-associated hemophagocytic syndromeA benign histiocytic proliferation distinct from malignant histiocytosis
|Cancer|1979|1.1k
Analysis of 462 Transplantations from Unrelated Donors Facilitated by the National Marrow Donor Program
|New England Journal of Medicine|1993|848
Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission
|New England Journal of Medicine|1998|610